Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

Fig. 1

Effects of 4 therapeutic regimens on levels of tPGEM, tPGDM and total urinary prostanoids. Levels of tPGEM (A), tPGDM (B) and total urinary prostanoids (C) concentrations were measured in urine samples collected at baseline (Day 0) and week 24. Prostanoid concentrations were normalized to creatinine levels. Total prostanoids also include PGIM and TXBM when their levels are quantifiable (> LLOQ). Comparisons were performed across all patients and within individual arms. GEE models were used and use of NSAIDs were adjusted in the model. *P < 0.05, **P < 0.01. ACT, Active Conventional Therapy arm; CZP, Certolizumab Pegol arm; ABA, Abatacept arm; TCZ, Tocilizumab arm; GEE, Generalized Estimating Equations; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us